ClinicalTrials.gg
Active, not recruitingNCT06866158Updated Dec 5, 2025

Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

A Phase 1/2 interventional study of Dendritic cell immunotherapy in Diabetic Kidney Disease (DKD), sponsored by PT. JES Kasih Nusantara Sejahterah. Active, not recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by PT. JES Kasih Nusantara Sejahterah · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus (T2DM) patients with Diabetic Kidney Disease (DKD). The main questions it aims to answer are:

  • Does autologous DC immunotherapy reduce urine albumin-creatinine ratio (UACR) in DKD patients?
  • What are the underlying mechanisms (modulation of inflammation, endothelial dysfunction, angiogenesis, fibrosis, and structural changes) through which DC immunotherapy reduces UACR in DKD patients?

Participants will:

  • Undergo collection of autologous dendritic cells, which will be matured ex vivo using SARS-CoV-2 S protein.
  • Receive a single subcutaneous injection consisting of matured dendritic cells and lymphocyte reinfusion.
  • Have UACR measured at baseline and at weeks 1, 2, 3, and 4 post-immunotherapy.
  • Undergo assessments of other laboratory parameters and kidney imaging (ultrasonography and/or magnetic resonance imaging) at baseline and week 4 post-treatment.
  • What is the effect of autologous DC immunotherapy on knee OA, assessed by radiographic changes (x-ray) and patient-reported outcomes (WOMAC score)?

Additionally, a subgroup of subjects who had neuropathy as comorbidity will be assessed using Electromyography (EMG) and the Toronto Clinical Neuropathy Scale (TCNS). These assessments aimed to determine the impact of the intervention on peripheral nerve function, clinical neuropathy symptoms over the study period. Another subgroup of subjects who had knee osteoarthritis will be assessed their knee x-ray and Western Ontario and McMaster Universities osteoarthritis index (WOMAC) score. These assessments aimed to determine the impact of the intervention on knee anatomic structure, function, and pain.

02

Conditions studied

  • Diabetic Kidney Disease (DKD)

Keywords

  • Dendritic Cell
  • Immunotherapy
  • Diabetic Kidney Disease
  • Cellular Therapy
  • Autologous
03

In context

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

This study's enrollment of 80 is close to the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.

Browse Diabetic Nephropathies studies →

Lead sponsor

This is the only study on the registry with PT. JES Kasih Nusantara Sejahterah as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female over 18 years old
  2. Understands and agrees to comply with study procedures by providing written .
  3. In the investigator's judgment, the subject is able and willing to comply with study procedures.
  4. In the investigator's judgment, the subject is in generally good physical and mental health. This includes the following factors:

    • Age > 65 years
    • Mild to moderate obesity ( 30 to 40)
    • Controlled hypertension with medication
    • Controlled hyperlipidemia with medication
    • Mild chronic lung disease
    • Previously diagnosed with cancer and in remission for at least 1 year
  5. Meets the diagnostic criteria for Type 2 Diabetes Mellitus (DM) according to Indonesia's Endocrinology Society (PERKENI) 2021.
  6. ≥ 30 mL/min/1.73 m².
  7. Urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g.

Exclusion criteria

Exclusion Criteria:

  1. Receiving treatments such as , hydroxychloroquine, methotrexate, cyclophosphamide, and others within the last 4 weeks.
  2. Known to have other kidney diseases (e.g., polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.).
  3. Known to have other conditions that can cause albuminuria (e.g., myeloma, rhabdomyolysis, paroxysmal nocturnal hemoglobinuria, orthostatic albuminuria, etc.).
  4. Diagnosed with other types of diabetes (Type 1 DM, gestational DM, or other forms of DM).
  5. Positive pregnancy test.
  6. Known to have immunodeficiency diseases such as (HIV), virus (HCV), or virus (HBV); no blood testing required.
  7. Requires oxygen supplementation.
  8. Diagnosed with invasive cancer and currently receiving anti-cancer therapy, except for hormonal therapy for breast or prostate cancer.
  9. History of thromboembolism or a genetic predisposition to thromboembolism, or currently on anti-thromboembolic therapy other than low-dose aspirin.
  10. Physical or mental disabilities preventing normal daily activities.
  11. In the investigator's judgment, any illness or medical condition that may hinder the subject's participation, including acute, subacute, intermittent, or chronic diseases that could place the subject at risk of injury, prevent compliance with the study protocol, or interfere with study assessments.
  12. Measurable parameters include:

    • Severe obesity: > 40
    • Uncontrolled hypertension: systolic >180 mmHg, diastolic >100 mmHg
  13. Unwilling to sign the written .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Autologous DCL

    Biological: Dendritic cell immunotherapy

Interventions

  • DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2. The number of cells given depends on individual yields.

    Also known as: Immunotherapy Nusantara

06

What researchers measure

Primary outcomes

  1. Change in Urine Albumin-Creatinine Ratio (UACR) from Baseline

    UACR were evaluated at a total 5 time points: baseline, week 1, 2, 3, and 4.

    Time frame: From baseline to 4 weeks after treament

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate

    Estimated glomerular filtration rate (eGFR) calculated from serum creatinine using the CKD-EPI equation.

    Time frame: From baseline to 4 weeks after treament

  2. Change in Angiogenesis Biomarker

    An angiogenesis biomarker, vascular endothelial growth factor (VEGF) were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  3. Change in Interleukin-6

    Interleukin-6 (IL-6), an inflammatory biomarker, was evaluated at both baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  4. Change in tumor necrosis factor-α

    Tumor necrosis factor-α (TNF-α), an inflammatory biomarker, was evaluated at both baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  5. Change in interleukin-10

    Interleukin-10 (IL-10), an inflammatory biomarker, was evaluated at both baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  6. Change in transforming growth factor-β

    Transforming growth factor-β (TGF-β), an endothelial biomarkers, were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  7. Change in matrix metalloproteinase-9

    Change in matrix metalloproteinase-9 (MMP-9), an endothelial biomarkers, were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in ng/mL.

    Time frame: From baseline to 4 weeks after treament

  8. Change in endhotelin

    Endhotelin, an endothelial biomarkers, were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in pg/mL.

    Time frame: From baseline to 4 weeks after treament

  9. Change in intercellular adhesion molecule

    Change in intercellular adhesion molecule (ICAM), an endothelial biomarkers, were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in ng/mL.

    Time frame: From baseline to 4 weeks after treament

  10. Change in vascular cell adhesion protein

    Change in vascular cell adhesion protein (VCAM), an endothelial biomarkers, were evaluated at baseline and 4 weeks post-treatment. With measurements expressed in ng/mL.

    Time frame: From baseline to 4 weeks after treament

  11. Change in kidney perfusion

    Doppler Ultrasonography (Doppler USG) of the kidneys were performed at baseline and 4 weeks post-treatment.

    Time frame: From baseline to 4 weeks after treament

  12. Change in kidney tissue and function

    Magnetic Resonance Imaging Diffusion Weighted Imaging (MRI DWI) of the kidneys were performed at baseline and 4 weeks post-treatment.

    Time frame: From baseline to 4 weeks after treament

  13. Change in kidney tissue and function

    Magnetic Resonance Imaging Diffusion Tensor Imaging (MRI DTI) of the kidneys were performed at baseline and 4 weeks post-treatment.

    Time frame: From baseline to 4 weeks after treament

Other outcomes

  1. Change in Nerve Conduction Velocity

    Changes in Nerve Conduction Velocity (m/s) as measured by Electromyography were conducted only on a subgroup of patients who had Neuropathy as a comorbidity and were assessed at two time points: baseline and 4 weeks post-treatment.

    Time frame: From baseline to 4 weeks after treament

  2. Change in Toronto Clinical Neuropathy Score

    Changes in Toronto Clinical Neuropathy Score (TCNS) were conducted only on a subgroup of patients who had Neuropathy as a comorbidity and were assessed at two time points: baseline and 4 weeks post-treatment.This scale is used to assess the severity of diabetic peripheral neuropathy. The score ranges from 0 to 15, with higher scores indicating worse neuropathy. It evaluates various clinical signs, such as the presence of symptoms like pain, numbness, and weakness, along with physical examination findings like ankle reflexes and vibration sensation. A higher score suggests more severe neuropathy and a worse outcome for the patient.

    Time frame: From baseline to 4 weeks after treament

  3. Knee X-ray

    Knee X-ray done on both knee and graded using Kellgren-Lawrence grading system

    Time frame: Baseline and 4 weeks after intervention

  4. The Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire for assessing pain, stiffness, and physical function in individuals with osteoarthritis of the hip or knee. The WOMAC is a 24-item tool that includes 5 questions on pain, 2 on stiffness, and 17 on physical function, with higher scores indicating worse symptoms.

    Time frame: Baseline to 4 weeks after intervention

07

Study locations

1 site
08

References and documents

Publications

  • Jonny J, Sitepu EC, Lister INE, Chiuman L, Putranto TA. The Potential of Anti-Inflammatory DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Vaccines (Basel). 2024 Aug 27;12(9):972. doi: 10.3390/vaccines12090972. PubMed 39340004 ↗
  • Setiawan E, Ginting CN, Jonny J, Hernowo BA, Putranto TA. Clinical Trial: Effect of Autologous Dendritic Cell Administration on Improving Neuropathy Symptoms and Inflammatory Biomarkers in Diabetic Neuropathy. Curr Issues Mol Biol. 2024 Dec 20;46(12):14366-14380. doi: 10.3390/cimb46120861. PubMed 39727989 ↗
  • Dimu PS, Icksan AG, Farhat, Jonny, Hernowo BA, Putranto TA. Clinical Trial of Autologous Dendritic Cell Administration Effect on Water Molecule Diffusion and Anti-Inflammatory Biomarkers in Diabetic Kidney Disease. Curr Issues Mol Biol. 2024 Dec 4;46(12):13767-13779. doi: 10.3390/cimb46120822. PubMed 39727950 ↗
  • Jonny, Sitepu EC, Hernowo BA, Chiuman L, Lister INE, Putranto TA. Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor alpha) in Diabetic Kidney Disease (DKD). Curr Issues Mol Biol. 2024 Dec 2;46(12):13662-13674. doi: 10.3390/cimb46120816. PubMed 39727944 ↗
  • Yana ML, Sitepu EC, Jonny, Chiuman L, Lister INE, Putranto TA. The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial. Curr Issues Mol Biol. 2025 Jan 6;47(1):31. doi: 10.3390/cimb47010031. PubMed 39852146 ↗

Individual participant data

Plan to share: Yes — Only individual participant data (IPD) underlying the results presented in the publication will be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Aug 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2025
First posted
Mar 10, 2025
StartActual
May 1, 2024
Primary completionActual
Aug 5, 2024
CompletionEst.
Aug 5, 2026
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06866158
Lead sponsor
PT. JES Kasih Nusantara Sejahterah
Collaborators
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto, Universitas Prima Indonesia, Universitas Pertahanan Indonesia
Responsible party
dr. Jonny, Sp.PD-KGH, M.Kes, M.M, DCN (Principal Investigator, Rumah Sakit Pusat Angkatan Darat Gatot Soebroto) — Principal investigator
First posted
Mar 10, 2025
Start date
May 1, 2024
Primary completion
Aug 5, 2024
Completion
Aug 5, 2026 (estimated)
Last update
Dec 5, 2025

Study contacts

dr Jonny, Sp.PD-KGH, M.Kes, M.M, DCN
principal investigator · Gatot Soebroto Central Army Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dendritic Cell

Start the discussion